Cancer cells drive the metabolic heterogeneity of breast cancer, with TNBC exhibiting distinct metabolic phenotypes and more pronounced dysregulation compared to luminal or HER2-enriched subtypes [6]. Here, ERBB2 is linked to breast cancer.